| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/20/2010 | WO2010054530A1 Method for preparing genetically engineered n-terminal acetylated thymosin alpha 1 |
| 05/20/2010 | WO2010054528A1 Quinazoline compounds |
| 05/20/2010 | WO2010054452A1 New compounds of the pterocarpanquinone family, method for preparing the same, pharmaceutical composition containing the new compounds of the pterocarpanquinone family, uses and therapeutic method |
| 05/20/2010 | WO2010054440A1 Bmp-7 compounds for modulating the expression of telomerase reverse transcriptase |
| 05/20/2010 | WO2010054438A1 Aryl di-substituted propenone compounds |
| 05/20/2010 | WO2010037395A3 Mhc multimers in cancer vaccines and immune monitoring |
| 05/20/2010 | WO2010036631A3 Sulfonyl compounds which selectively modulate the cb2 receptor |
| 05/20/2010 | WO2010036630A3 Sulfonyl compounds which selectively modulate the cb2 receptor |
| 05/20/2010 | WO2010036407A3 Antiviral nucleoside analogs |
| 05/20/2010 | WO2010035259A3 Compositions comprising soluble cd84 or anti-cd84 antibodies and methods for diagnosing and treating b-cll |
| 05/20/2010 | WO2010032008A3 Dendritic cell modulatory molecule |
| 05/20/2010 | WO2010030314A3 Aberrant expression of cks1 and cks2 and uses thereof |
| 05/20/2010 | WO2010017550A3 Lipid compounds for supression of tumorigenesis |
| 05/20/2010 | WO2010014933A3 Psma-binding agents and uses thereof |
| 05/20/2010 | WO2010011315A3 Proteins for use in diagnosing and treating infection and disease |
| 05/20/2010 | WO2010006162A3 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs |
| 05/20/2010 | WO2010002983A3 Composition and methods for eliciting an immune response |
| 05/20/2010 | WO2009133204A3 Vector for use in medicine |
| 05/20/2010 | US20100125131 Gene Encoding A Guanine Nucleotide Exchange Factor And The Gene Product Thereof |
| 05/20/2010 | US20100125130 Tumour necrosis factor binding ligands |
| 05/20/2010 | US20100125101 Immunostimulatory nucleic acid molecules |
| 05/20/2010 | US20100125098 Treatment of cancer with complex organic-inorganic pigment compositions |
| 05/20/2010 | US20100125094 Pyrrolidinyl modulators of nicotinic acetylcholine receptors |
| 05/20/2010 | US20100125084 Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine |
| 05/20/2010 | US20100125073 Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system |
| 05/20/2010 | US20100125068 Methods for inhibiting protein kinases |
| 05/20/2010 | US20100125064 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases |
| 05/20/2010 | US20100125055 Muc-1 cytoplasmic domain peptides as inhibitors of cancer |
| 05/20/2010 | US20100125051 Parenteral Formulations Comprising Sugar-Based Esters and Ethers |
| 05/20/2010 | US20100124573 Extracellular matrix compositions for the treatment of cancer |
| 05/20/2010 | US20100124555 Compositions and Methods for Treating Pancreatic Tumors |
| 05/20/2010 | US20100124546 Adenovirus With Mutations in the Endoplasmic Reticulum Retention Domain of the E3-19K Protein and Their Use in Cancer Treatment |
| 05/20/2010 | US20100124544 Crystalline forms of dihydropyrazolopyrimidinone |
| 05/20/2010 | DE102008057364A1 New pyridyl or phenyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy |
| 05/20/2010 | DE102008057344A1 Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung Aminoalkyl-substituted aryl compounds, and their use |
| 05/20/2010 | DE102008057343A1 New phenyl or pyridyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy |
| 05/20/2010 | CA2743904A1 Cancer vaccine compositions and methods of using the same |
| 05/20/2010 | CA2743902A1 Substituted dioxopiperidinyl phthalimide derivatives |
| 05/20/2010 | CA2743871A1 Extracellular matrix compositions for the treatment of cancer |
| 05/20/2010 | CA2743709A1 Treatment of proteinopathies using a farnesyl transferase inhibitor |
| 05/20/2010 | CA2743661A1 Aryl di-substituted propenone compounds |
| 05/20/2010 | CA2743642A1 Therapies for hematologic malignancies |
| 05/20/2010 | CA2743449A1 Pyrazinopyrazines and derivatives as kinase inhibitors |
| 05/20/2010 | CA2743426A1 New crystal form of sunitinib malate |
| 05/20/2010 | CA2743305A1 Anti-cxcr1 compositions and methods |
| 05/20/2010 | CA2743295A1 P70 s6 kinase inhibitor and egfr inhibitor combination therapy |
| 05/20/2010 | CA2743264A1 Tetrasubstituted pyridazines hedgehog pathway antagonists |
| 05/20/2010 | CA2743242A1 P70 s6 kinase inhibitor and mtor inhibitor combination therapy |
| 05/20/2010 | CA2743073A1 2,4-diaminopyrimidine derivates as ptk2- inhibitors for the treatment of abnormal cell growth |
| 05/20/2010 | CA2743019A1 Akt and p70 s6 kinase inhibitors |
| 05/20/2010 | CA2743015A1 Pi3k/mtor kinase inhibitors |
| 05/20/2010 | CA2742990A1 Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
| 05/20/2010 | CA2742297A1 Pyridine, bicyclic pyridine and related analogs as sirtuin modulators |
| 05/20/2010 | CA2741929A1 Suppression of cancer |
| 05/20/2010 | CA2741096A1 Triterpenoid 2-deoxy glycosides, method of preparation thereof and use thereof as medicaments |
| 05/19/2010 | EP2186901A2 Mutations in the BCR-Abl-tyrosine kinase associated with resistance to STI-571 |
| 05/19/2010 | EP2186896A1 Cancer antigen peptides derived from WT1 |
| 05/19/2010 | EP2186892A1 Anti-cd20 monoclonal antibodies |
| 05/19/2010 | EP2186830A1 Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof |
| 05/19/2010 | EP2186810A1 Poly-heteroaryl derivatives for the treatment of cancer |
| 05/19/2010 | EP2186809A1 New crystal form of sunitinib malate |
| 05/19/2010 | EP2186808A1 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 05/19/2010 | EP2186806A1 Flavanone compound and uses thereof |
| 05/19/2010 | EP2186530A1 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/19/2010 | EP2186529A2 Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
| 05/19/2010 | EP2186524A1 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| 05/19/2010 | EP2186519A1 Use of adenosine aspartate for the preparation of pharmaceutical products for the treatment of liver cancer |
| 05/19/2010 | EP2186514A1 Treatment of Malignant Peripheral Nerve Sheath Tumors |
| 05/19/2010 | EP2186513A1 Use of specific cyclolignans |
| 05/19/2010 | EP2185933A2 Matriptase protein and uses thereof |
| 05/19/2010 | EP2185568A2 Therapeutic compounds |
| 05/19/2010 | EP2185562A1 Pyrrolopyrimidines |
| 05/19/2010 | EP2185559A1 Crystalline form of a dihydropteridione derivative |
| 05/19/2010 | EP2185557A2 Perharidines as cdk inhibitors |
| 05/19/2010 | EP2185556A1 Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 05/19/2010 | EP2185555A1 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 05/19/2010 | EP2185541A1 Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53 |
| 05/19/2010 | EP2185537A1 Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions |
| 05/19/2010 | EP2185523A2 Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics |
| 05/19/2010 | EP2185521A2 Compounds and methods for modulating rho gtpases |
| 05/19/2010 | EP2185511A2 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof |
| 05/19/2010 | EP2185204A2 Conjugate comprising a selective estrogen receptor modulator and a ribosome inactivating toxin |
| 05/19/2010 | EP2185203A1 Oxidized avidin with high residency time in the treated tissues |
| 05/19/2010 | EP2185198A1 Lox and l0xl2 inhibitors and uses thereof |
| 05/19/2010 | EP2185181A2 Therapeutic uses of gastrin-1 and g-pen-grgdspca |
| 05/19/2010 | EP2185177A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent |
| 05/19/2010 | EP2185176A2 Vhz for diagnosis and treatment of cancer |
| 05/19/2010 | EP2185173A1 Use of phosphatases to treat neuroblastomas and medullogastomas |
| 05/19/2010 | EP2185171A2 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents |
| 05/19/2010 | EP2185164A1 Composition and therapeutic anti-tumour vaccine |
| 05/19/2010 | EP2184987A1 Bi-dentate compounds as kinase inhibitors |
| 05/19/2010 | EP1899335B1 Pyrroloquinoline derivatives and their use as protein kinase inhibitors |
| 05/19/2010 | EP1720611B1 Diagnostic marker for cancer |
| 05/19/2010 | EP1599467B1 Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| 05/19/2010 | EP1485380B1 Azolylaminoazines as inhibitors of protein kinases |
| 05/19/2010 | EP1467995B1 Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
| 05/19/2010 | EP1463487B1 Liposomal delivery of vitamin e based compounds |
| 05/19/2010 | EP1371646B1 Aryl-substituted alicyclic compound and medical composition comprising the same |
| 05/19/2010 | EP1214097B9 Nucleic acids encoding polyepitope polypeptides |
| 05/19/2010 | EP1180991B1 Gambogic acid derivatives as activators of caspases and inducers of apoptosis |